Draft:Raymond Blind
 | Review waiting, please be patient.
This may take 2–3 weeks or more, since drafts are reviewed in no specific order. There are 1,256 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Comment: In accordance with Wikipedia's Conflict of interest guideline, I disclose that I have a conflict of interest regarding the subject of this article. Mitchell2526 (talk) 20:09, 3 September 2026 (UTC)
Raymond Blind is an Ingram Associate Professor of Cancer Research at the Vanderbilt University Medical Center,[1] an Associate Professor of Medicine in the Division of Diabetes, Endocrinology & Metabolism,[2] and has secondary appointments in biochemistry and pharmacology at the Vanderbilt University School of Medicine.[1] Blind is also the Director of Vanderbilt's Quantitative & Chemical Biology program.[3] He is an active member of the Vanderbilt Institute of Chemical Biology,[4] Vanderbilt Center for Structural Biology,[5] and Vanderbilt-Ingram Cancer Center.[1][3][6]
Early life and education
[edit]Blind was born in Buffalo, NY. He received his B.S in Molecular Genetics at Fredonia State College.[7] Blind graduated with his Ph.D. in pharmacology at New York University. He did postdoctoral research in pharmaceutical chemistry at the University of California San Francisco in 2006.[7] [8]
Research
[edit]Blind's research explores second messenger signaling in the nucleus.[8] The nucleus of every eukaryotic cell contains a pool of phosphoinositide lipids that do not exist in a bilayer structure, but are complexed to proteins.[9] His lab uses structural biology, functional genomics and chemical biology to study how nuclear signaling events regulate gene expression,[7] specifically, the signaling properties of nuclear inositide lipids and inositol phosphates.[8]
Blind's research has discovered how liver and endometrial cancers in African Americas and Hispanics continue to grow. A protein controls organ growth by placing a "molecular barcode" on the DNA.[10] By testing the barcodes, this allows Blind's lab to develop new therapies for liver cancer patients.[10]
Honors and awards
[edit]Blind has received the following honors and awards:[11]
- 2020 - Genetics Society of America Presidential Membership Award
- 2018 - Vanderbilt Trans-Institutional Program Award
- 2018 - Journal of Lipid Research Junior Investigator Award
- 2017 - Vanderbilt Diabetes Discovery Award
- 2017 - American Cancer Society Research Scholar Award
- 2017 - Vanderbilt Diabetes RTC Award
- 2017 - Jimmy-V Foundation V-Scholar Award
- 2016 - Vanderbilt Young Ambassador Award
- 2016 - Herb Tabor / JBC Young Investigator
Selected publications
[edit]- Wang, H.; Shears, S. B.; Blind, R. D. (2025). "Structural Rationalization of IPMK Inhibitor Potency". Journal of Medicinal Chemistry. 68 (22): 24316–24325. doi:10.1021/acs.jmedchem.5c02314. PMID 41237254.
- Haratipour, Z.; Foutch, D.; Blind, R. D. (2024). "A novel heuristic of rigid docking scores positively correlates with full-length nuclear receptor LRH-1 regulation". Computational and Structural Biotechnology Journal. 23: 3065–3080. doi:10.1016/j.csbj.2024.07.021. PMID 39185441.
- Malabanan, M. M.; Chapagain, P.; Haratipour, Z.; Choi, W. J.; Orun, A. R.; Blind, R. D. (2023). "New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1". ACS Chemical Biology. 18 (5): 1101–1114. doi:10.1021/acschembio.2c00805. PMID 37074920.
- Blind, R. D.; Sablin, E. P.; Kuchenbecker, K. M.; Chiu, H. J.; Deacon, A. M.; Das, D.; Fletterick, R. J.; Ingraham, H. A. (2014). "The signaling phospholipid PIP3 creates a new interaction surface on the nuclear receptor SF-1". Proceedings of the National Academy of Sciences of the United States of America. 111 (42): 15054–15059. doi:10.1073/pnas.1416740111. PMID 25288771.
External links
[edit]- Raymond D. Blind publications at PubMed
References
[edit]- 1 2 3 "The Blind Lab | Vanderbilt". home. Retrieved 2026-09-03.
- ↑ "User Detail | Department of Medicine". medicine.vumc.org. Retrieved 2026-09-03.
- 1 2 "QCB Leadership Team". Vanderbilt University. Retrieved 2026-09-03.
- ↑ "Our Team". Vanderbilt University. Retrieved 2026-09-03.
- ↑ "CSB Core Faculty". csb.vanderbilt.edu. Retrieved 2026-09-03.
- ↑ "Blind [142108] | Vanderbilt-Ingram Cancer Center". vicc.org. Retrieved 2026-09-03.
- 1 2 3 "Nuclear second messenger signaling: How phospholipids, bilirubin and inositol phosphates directly control gene expression". www.asbmb.org. Retrieved 2026-09-03.
- 1 2 3 "User Detail | Department of Medicine". medicine.vumc.org. Retrieved 2026-09-03.
- ↑ Philosophy, Doctor of; University, Professor (Assistant) at Vanderbilt. "Raymond BLIND | Professor (Assistant) | Doctor of Philosophy | Vanderbilt University, Nashville | Vander Bilt | Department of Pharmacology | Research profile". ResearchGate. Retrieved 2026-09-03.
- 1 2 "Raymond Blind, Ph.D." V Foundation. Retrieved 2026-09-03.
- ↑ "The Blind Lab | People". home. Retrieved 2026-09-03.